Send us Fan Mail

Dr. Fakhoury discusses the use of systemic treatment for patients with severe alopecia areata. He highlights data from the THRIVE-AA1 and THRIVE-AA2 clinical trials, which showed effective results with deuruxilitinib vs placebo in this patient population. Additionally, he emphasizes that the indications for severe alopecia areata have expanded to those with a Severity of Alopecia Tool (SALT) score of 20 to 49 and outlined patient populations who could benefit from treatment with deuruxolitinib. 

Send us Fan Mail

Dr. Chovatiya reviews generalized pustular psoriasis (GPP) as a distinct, potentially life-threatening inflammatory dermatosis characterized by acute flares and periods of relative quiescence. He highlights the diagnostic challenges in differentiating GPP from plaque psoriasis and other pustular disorders, as well as the central role of interleukin (IL)-36 pathway dysregulation in driving neutrophilic inflammation. He also reviews the use of intravenous therapy for rapid management of active flares and subcutaneous therapy for long-term flare prevention, and how these formulations may be incorporated across the disease course to support both acute control and ongoing GPP management. 

Send us Fan Mail

Dr. Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the August 2026 issue of JCAD.

Send us Fan Mail

Dr. Cohen discusses the treatment of psoriasis in high-impact sites. He outlines how to approach these special considerations and provides treatment options, including the utilization of biologics like risankizumab. He also reviews considerations for unique cases such as nail psoriasis and palmoplantar psoriasis.

Send us Fan Mail

Ahead of National Generalized Pustular Psoriasis (GPP) Awareness Day, Dr. Hawkes gives an overview of the distinct clinical and immunologic features of GPP, emphasizing how this rare, life-threatening disease differs from plaque psoriasis in both presentation and underlying pathophysiology. He highlights the central role of interleukin-36 (IL-36) dysregulation in GPP, explains why therapies developed for plaque psoriasis often do not provide adequate control of the disease, and outlines the rationale for IL-36 receptor inhibition as a targeted treatment strategy. Dr. Hawkes also discusses the practical use of spesolimab for both acute flares and long-term maintenance, including patient selection, dosing approaches, and the rapid clinical responses observed with intravenous therapy.

Send us Fan Mail

James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the July 2026 issue of JCAD.

Send us Fan Mail

Fabrizio Galimberti, MD, PhD, reviews the molecular biology behind spesolimab for the treatment of generalized pustular psoriasis (GPP). He highlights the distinction between psoriasis and GPP, while discussing the role that the interleukin-36 pathway plays in inflammation. Dr. Galimberti emphasizes the importance of targeted treatment for flare reduction and improved outcomes in GPP management.

Send us Fan Mail

James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the June 2026 issue of JCAD.

Send us Fan Mail

Tina Bhutani, MD, MAS, FAAD, discusses the use of spesolimab, an interleukin-36 receptor blocker, for the treatment of patients with generalized pustular psoriasis. Drawing on real-world patient cases, she highlights its role in rapidly controlling acute flares, improving patient quality of life, and reducing reliance on therapies originally developed for plaque psoriasis.

Send us Fan Mail

James Del Rosso, DO, the Editor-in-Chief of the Journal of Clinical and Aesthetic Dermatology, discusses highlights from new research published in the May 2026 issue of JCAD.